A clinical trial studying bariatric surgery as a radical treatment for type 2 diabetes has commenced in Europe:
Instead, investigators have found, bariatric surgery, independent of weight loss, alters metabolic factors such as the hunger-regulating peptide hormone ghrelin (as a result of decreased gastric mass). In addition, bariatric surgery results in increases in peptide YY which has an effect on satiety, and GLP-1, which affects gastric motility and beta-cell mass.
ADVERTISEMENT
Get free updates delivered free to your inbox.
Search thousands of physician, PA, NP, and CRNA jobs now.
Comments are moderated before they are published. Please read the comment policy.
